We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Endometriosis Therapy Linked to Ovarian Cancer

By HospiMedica staff writers
Posted on 26 Mar 2002
A study has found that women taking danazol for treating endometriosis were nearly three times more likely to develop ovarian cancer than women taking leuprolide. More...
The study, conducted by researchers at the University of Pittsburgh Graduate School of Public Health (PA, USA) was presented at the annual meeting of the Society of Gynecologic Oncologists in Miami (FL, USA).

Danazol is a synthetic version of the male hormone androgen, while leuprolide is an anti-androgenic, gonadotropin-releasing hormone agonist. The study pooled data from two case-control studies that examined the relationship among endometriosis, endometriosis treatments, and ovarian cancer in 32 women. According to the researchers, previous studies have found that women with endometriosis already have a 50% increased risk for ovarian cancer. Treating them with danazol appeared to further increase their risk. Women who took leuprolide had no significant risk elevation.

"While the number of women studied is small, the results are telling, and they warrant further studies on a larger scale,” said Carrie Cottreau, Ph.D., assistant professor of obstetrics and gynecology at the University of Pittsburgh School of Medicine. Additional studies are planned.




Related Links:
Pitts.School of Public Health

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Mobile X-Ray System
K4W
Ultrasound Needle Guidance System
SonoSite L25
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The 3D-printed microneedle patch boosts live-virus vaccine delivery (Photo courtesy of IIS/University of Tokyo)

3D-Printed Delivery System Enhances Vaccine Delivery Via Microneedle Array Patch

The COVID-19 pandemic underscored the need for efficient, durable, and widely accessible vaccines. Conventional vaccination requires trained personnel and cold-chain logistics, which can slow mass immunization... Read more

Surgical Techniques

view channel
Image: The AI-based approach identifies lipid regions matched well with histopathology results (Photo courtesy of Hyeong Soo Nam/KAIST)

AI-Based OCT Image Analysis Identifies High-Risk Plaques in Coronary Arteries

Lipid-rich plaques inside coronary arteries are strongly associated with heart attacks and other major cardiac events. While optical coherence tomography (OCT) provides detailed images of vessel structure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.